<DOC>
	<DOCNO>NCT00546988</DOCNO>
	<brief_summary>The study evaluate whether risk-stratification mean chromosomal aberration provide tool discriminate standard high risk . Risk-adapted therapy base allogeneic stem-cell transplantation high-risk subject instead second autograft patient deletion chromosome 13 HLA-identical stem cell donor available .</brief_summary>
	<brief_title>Multi Centre Trial DSMM Newly Diagnosed Multiple Myeloma 60 Years</brief_title>
	<detailed_description>The DSMM V protocol compare consolidation treatment standard-risk patient display del ( 13 ) initial diagnosis follow two cycle high-dose melphalan 200 mg/mÂ² support autologous stem cell retransfusion interferon versus PEG-interferon . Patients del ( 13 ) screen availability fully HLA-matched related unrelated donor . If patient 's informed consent obtain additionally , schedule undergo allogeneic SCT follow first cycle high-dose melphalan . All subject proceed second course high-dose melphalan similar standard-risk group . Initial cytoreduction foresee four cycle anthracycline-dexamethasone combination follow combination therapy ifosfamide/epirubicine/etoposide stem-cell collection .</detailed_description>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<criteria>Primary diagnosis multiple myeloma SalmonandDurie stage II III Less equal 60 year Signed informed consent Relevant comorbidities Unable adhere study protocol Pregnancy Not receive subject 's informed consent</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>October 2007</verification_date>
	<keyword>primary treatment</keyword>
	<keyword>allogeneic stem-cell transplantation</keyword>
	<keyword>high-dose therapy</keyword>
	<keyword>cytogenetics</keyword>
</DOC>